GGD

News

AWARD - ALAIN DUMONT

2014-04-10

Goudreau Gage Dubuc is proud to announce that Mr. Alain Dumont, Patent Agent, is a winner of the Client Choice Awards 2014 in the intellectual property - Patents category in Quebec. This award recognizes firms and individuals that stand apart for the excellent client care they provide. Winners are selected by International Law Office and Lexology based upon an international survey with general counsels. The criteria for this recognition focus on an ability to add real value to client’s business above and beyond the other players in the market. Client Choice Guide- USA & Canada 2014

Interview with Alain M. Leclerc

2013-10-21

The co-managing partner of one of Canada's leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients, and the incentive schemes in place to bring innovation to Canada. Read this interview on
PharmaBoardRoom.com

STEVEN LAM SCORES HIGHEST MARK IN PATENT DRAFTING EXAM IN CANADA

2013-09-03

Goudreau Gage Dubuc is proud to announce that Steven Lam, Patent Agent, obtained the highest overall mark in Canada on Paper A (patent drafting) of the 2012 Patent Agent exams.  He will thus receive the prestigious Marie F. Morency Memorial Prize during the 87th Annual Meeting of the Intellectual Property Institute of Canada (IPIC) in September 2013.

Steven’s practice is focused on the preparation of patent applications and the procurement of domestic and foreign patent rights, as well as providing strategic counseling on patentability, validity, infringement and regulatory matters, in the areas of biotechnology, pharmaceuticals and medical devices.  Steven joined GGD’s life sciences team in July 2008, following doctoral studies in biochemistry and post-doctoral research in the pharmaceutical industry

GGD receives Canadian IP Rising Star Award

2013-06-26

At its 2013 Awards Ceremony on June 20, 2013, the New York International Legal Alliance Summit & Awards proudly presented Alain M. Leclerc with the "Canadian IP Rising Star 2013" prize awarded to Goudreau Gage Dubuc.  GGD is among the few high potential IP practices recognized for their remarkable evolution.

See Press Release

From Science to Law

2013-05-23

LET THE LEADERS SPEAK!

Dominique Tardif from ZSA meets with Alain Leclerc, Co-Manager of Goudreau Gage Dubuc since 2006 and partner of the firm since 1994... (the following text is in French only)



(released by "Droit Inc. on May 22, 2013)
Click here to see the article on "Droit Inc." web site

1. Pourquoi avez-vous, à l’origine, décidé d’être avocat plutôt que de choisir un autre métier?

A l’origine, j’avais choisi le génie chimique, rien de moins! L’inspiration venait d’un professeur du secondaire qui avait pris un étudiant turbulent sous son aile pour en faire un amoureux de la science, ajoute-t-il avec humour.

Je me suis cependant ensuite rendu compte que tout m’intéressait: la science, l’économie, la politique, le droit, les sports, les médias, les arts, etc. Encore aujourd’hui, rien ne me déplaît, sauf d’être totalement ignorant sur un sujet donné; le choix de carrière fut donc difficile.

J’ai trouvé la combinaison science et droit en me spécialisant dans le domaine de la propriété intellectuelle, plus particulièrement en brevets d’invention…et je suis comblé! En fait, c’est de la chance que d’avoir un travail si varié. Je ne m’ennuie jamais : chaque dossier diffère du précédent, la science évolue, de même que le droit. Puisque ma pratique est internationale, j’ai aussi beaucoup de contacts avec l’étranger. Bref, je me considère très chanceux!

2. Quel est le plus grand défi professionnel auquel vous avez fait face au cours de votre carrière

Le défi fut sans contredit d’avoir à conjuguer travail et famille, étant moi-même père de trois enfants aujourd’hui adolescents, et de savoir maintenir l’équilibre. Chez GGD, je travaille sur les dossiers eux-mêmes en plus de m’impliquer, comme co-directeur du cabinet, dans tous les aspects de la gestion du bureau et du développement des affaires.

En parallèle de mes fonctions de gestion, je dessers une vaste clientèle située partout dans le monde et opérant dans des fuseaux horaires variés.

Ajoutons à cela les voyages, conférences et litiges devant les tribunaux, et vous constaterez qu’il manque parfois d’heures dans une journée! Le grand défi est donc de savoir s’organiser, de travailler en équipe, de savoir dire non et d’avoir malgré tout un sentiment de devoir accompli.

Il faut savoir être réaliste par rapport à ce qui peut être accompli dans une seule et même journée.

Ce défi est évidemment le lot de bien des avocats, mais je dois dire que j’ai eu la chance de pouvoir choisir de travailler au sein d’un cabinet qui vise et permette cet équilibre, et qui a des expectatives plus raisonnables que bien d’autres quant aux heures facturables, ce qui non seulement détend l’atmosphère mais permet aussi parfois d’accomplir plus! En effet, s’il faut bien sûr travailler fort, rappelons-nous que l’expérience démontre que trop d’heures travaillées peuvent diminuer le rendement et la créativité.

3. Si vous aviez une baguette magique, que changeriez-vous à la pratique du droit?

Dans mon domaine, la propriété intellectuelle, les délais et les coûts sont souvent excessifs. En revanche, les enjeux financiers sont souvent cruciaux pour les clients dans des domaines d’innovation, comme c’est le cas notamment pour l’industrie pharmaceutique. Perdre un brevet sur un produit vedette peut anéantir 15 ans de travail et mettre en péril la survie même d’une compagnie. Il n’est donc pas question d’arriver à procès sans avoir déployé tous les efforts possibles, et cela est coûteux pour le client.

Plusieurs améliorations sont cependant déjà à l’essai: juges diplômés en sciences (question d’éviter d’avoir à expliquer la science avant d’en venir à expliquer le droit), procédures sommaires ou accélérées, incitatifs pour faire en sorte que les experts des parties opposées définissent ensemble accords et désaccords, gestion plus serrée des délais et des questions en litige, etc.

En fait, la baguette magique, si j’en avais une, ferait en sorte d’arriver aux enjeux plus vite et sans détour!

4. La perception du public envers la profession et les avocats en général est-elle plus positive, égale ou moins positive qu’elle ne l’était lors de vos débuts en pratique? Et pourquoi, à votre avis?

Je crois que la perception est à peu près égale à ce qu’elle était à mes débuts. Les avocats sont en même temps respectés, d’une part, et remis en question, d’autre part : ils sont respectés pour leur talent, mais remis en question pour leurs nombreuses tactiques.

Je pense cela dit que le rôle de l’avocat est en mutation. En effet, l’avocat est de plus en plus appelé à baliser et entourer la bonne conduite des affaires plutôt que d’être appelé à la rescousse après que les litiges soient survenus. Son rôle est de plus en plus situé en amont du problème, ce qui, d’après moi, contribuera à une perception plus positive du public envers la profession dans les années à venir.

5. Quel conseil donneriez-vous à quelqu’un débutant sa carrière et souhaitant réussir en pratique privée dans le domaine de la propriété intellectuelle?

D’abord, soignez vos communications écrites et verbales et développez votre écoute; apprenez à vous relire, à vous corriger et à bien adapter votre discours aux circonstances, en évitant les formules ‘prévues d’avance’.

Comme nous en sommes à l’ère des spécialisations, j’encouragerais aussi les jeunes avocats à exploiter des créneaux d’avenir qui semblent encore inoccupés ou qui sont en émergence. Ensuite, trouvez un moyen de publiciser cette expertise par le biais de conférences, des réseaux sociaux, etc., et ayez un message court et simple.

Finalement, sachez démontrez de l’empathie pour les clients : cela ouvre beaucoup de portes. Il est en effet essentiel de comprendre les enjeux des clients avant de proposer des solutions, de ‘se mettre dans leurs souliers’ et, tout simplement, de traiter leurs affaires comme si elles étaient les nôtres. Réfléchissez, et soyez patients. Cette approche fait toute la différence quand il s’agit de fidéliser les clients et d’obtenir des recommandations.

En vrac…

• Le dernier bon livre qu’il a lu – "22/11/63" (auteur : Stephen King)

• Le dernier bon film qu’il a vu– Skyfall (réalisateur : Sam Mendes)

• Sa chanson fétiche – Holding back the years (Simply Red)

• Son expression préférée – « La vie est comme une boîte de chocolats, on ne sait jamais sur quoi on va tomber » - Forrest Gump

• Son péché mignon – ou plutôt ses péchés mignons au pluriel, il en a plus d’un! : sushis, chocolats noir fleur de sel, champagne, fromages, whisky, etc.

• Son restaurant préféré – Koji Kaizen (rue Sainte-Catherine)

• Le pays qu’il aimerait visiter – L’Afrique du Sud

• Le personnage historique qu’il admire le plus (et pourquoi?) – Martin Luther King, pour ses discours et son message.

• S’il n’était pas avocat, il serait… chef dans un grand hôtel !

BIO

Me Alain M. Leclerc est co-directeur de Goudreau Gage Dubuc depuis 2006, et associé au sein du cabinet depuis 1994. Il supervise les opérations du secteur brevets et préside le groupe de pratique en chimie.

Me Leclerc est titulaire d'un diplôme en génie chimique de l'Université d'Ottawa et est avocat admis au Barreau du Québec depuis 1991 et au Barreau du Haut-Canada depuis 1992. Il est inscrit aux registres des agents de brevets au Canada et aux États-Unis et des agents de marques de commerce au Canada.

En plus d'une importante pratique en rédaction et obtention de brevets au Canada et à l'étranger, son expertise est mise à contribution dans les domaines du litige en propriété intellectuelle et de l'octroi de licences.

Me Leclerc est aussi particulièrement actif en litiges pharmaceutiques, en arbitrage, en revues diligentes transactionnelles et en développement de stratégies commerciales reliées aux brevets.

Me Leclerc présente fréquemment des conférences en propriété intellectuelle lors de congrès ou d’événements clients.


GREAT NEWS FOR DUCHESNAY

2013-04-11

Duchesnay Inc., a Quebec pharmaceutical company, sets for international expansion following the FDA approval of its morning sickness medication Diclegis® for pregnant women.  Diclegis® has been available in Canada for some years under the trade-mark Diclectin®.

Duchesnay’s team is working at advancing maternal-fetal medicine and scientific knowledge to reduce the risk of birth defects and help women fully enjoy their pregnancy while ensuring their own health and that of their babies.

For more information on this announcement:   Duchesnay

NOMINATION

2013-04-02

We are proud to announce that the New-York International Legal Alliance Summit & Awards has selected Goudreau Gage Dubuc to receive a Rising Star Award. This award recognizes GGD as a leading intellectual property firm, which has demonstrated its ability to provide efficient services in complex deals and to gain new market shares.

ILASA

World Intellectual Property Day

2013-04-01

On April 26 every year, the World Intellectual Property Organization (WIPO) celebrates the “World Intellectual Property Day”.  It aims to increase people’s awareness and understanding of intellectual property contribution to the development of innovation and creativity.

In 2013, World IP Day focuses on “Creativity: The Next Generation”.

You can find more details on WIPO web site.

BÉATRICE T. NGATCHA, Speaker

2012-11-05

BÉATRICE T. NGATCHA, Patent Agent in the chemical sector, is invited to present a conference entitled "Le brevet - Plus qu'une protection, un outil de commercialisation" at the Corporation de développement économique communautaire Rosemont-Petite-Patrie, on Wednesday, November 21, 2012, from 8 to 10 AM.  You will find registration instructions and additional information on cdec-rpp.ca.

CHARLES GOYER, member of the Steering Committee of the Mentorat bio Succès network

2012-09-19

Mr. Charles Goyer, Patent Agent, has been nominated to the Steering Committee of the Mentorat bioSuccès network as the representative of the Board of Directors of Montréal InVivo.

Mentorat bioSuccès is a provincial mentoring network for entrepreneurs specialized in the life sciences and health technologies (LSHT) sector.  Its mission is to improve the success of LSHT entrepreneurs by offering them the support of quality mentors intent on sharing their successful entrepreneurial or corporate leadership in the sector.

APPOINTMENT

2012-06-12

Alain M. Leclerc was elected President of FICPI CANADA for a three-year term ending in 2015.  The election was held during the April 2012 FICPI World Congress in Melbourne, Australia.  He is assisted in his duties by a dedicated Council of five top notch professionals from other Canadian IP firms.

ABOUT FICPI CANADA

FICPI (Fédération Internationale des Conseils en Propriété Intellectuelle) is a non-for-profit organization headquarted in Switzerland and having a total membership of over 5000 intellectual property attorneys/agents in private practice in over 86 countries around the world.

FICPI CANADA is the self-governing national association of FICPI representing the interests of Canadian patent, design and trade-mark professional members.  Membership includes senior professionals at most major intellectual property firms, the same professionals who are responsible for filing the vast majority of patent, industrial design and trade-mark applications submitted to the Canadian Intellectual Property Office (CIPO) each year.  Members' clients represent all types and sizes of businesses, including multinational corporations, small and medium size enterprises, and individuals.

FICPI CANADA holds frequent meetings with top officials from CIPO, prepares submissions to the Canadian government on legislative, regulatory and procedural matters related to intellectual property, organizes meetings for its members, attends various FICPI events throughout the world as a Canadian delegation, and holds claim drafting clinics and legal opinion drafting clinics for Canadian IP professionals.

FICPI CANADA

JULIE GAUVREAU and ISABELLE PELLETIER speakers

2012-06-11

Julie Gauvreau and Isabelle Pelletier, Patent Agents, are speakers at the conference series Innover c’est bien… breveter c’est mieux! (Innovating is good... patenting is better).  They will host the workshop held in Sherbrooke, on June 14, Le brevet – Démarches, frais et délais (Patent: process, fees dans deadlines).  They will also co-host with Caroline Lefebvre from OPIC, the workshops Les différentes formes de propriétés intellectuelles (various forms of intellectual property) and Étude de cas – AUTOPAINT (Study Case : AUTOPAINT).

This conference series is meant for economic development organizations and IP professionals throughout the province of Québec.  Six series of conferences were presented in 2012 to businessman and to small and medium-sized firms.

2012 Conference Series

GGD, A RISING STAR

2012-05-16

Goudreau Gage Dubuc is pleased to have achieved in 2011 the strongest percentage growth in patent application filings amongst the top 12 IP firms in Canada.  GGD has increased its volume of patent application filings by 14.5% over 2010, despite a shrinking market.  For the GGD team, client service is front and center and a key part of the success equation.
IP Practice.ca

NOMINATION

2012-04-02

We are proud to announce that the New-York International Legal Alliance Summit & Awards has selected Goudreau Gage Dubuc to receive a Rising Star Award. This award recognizes GGD as a leading intellectual property firm, which has demonstrated its ability to provide efficient services in complex deals and to gain new market shares.

ILASA

NOMINATION

2012-03-28

Goudreau Gage Dubuc is proud to announce the nomination of Chantal Desjardins and Isabelle Jomphe as Leading Trademark Professionals by the World Trademark Review 1000 - 2012 Edition.  At the vanguard of the practice, Chantal Desjardins is a renowned practitioner in the fields of enforcement and litigation as well as prosecution and strategy.  Me Jomphe is also selected as a strong expert successfully involved in trademark prosecution, strategy, and portfolio management.
WTR 1000 site

GREAT NEWS

2012-03-26

Lumira Capital II Funds provide financial support in life science sector in Québec.  Montréal InVivo is proud to announce the launch on March 26th of two funds, managed by Lumira Capital, to stimulate innovation in life sciences and healthcare industry in Québec.  The Merck Lumira Biosciences Fund will invest predominantly in biotechnology (35M$) while the Lumira Capital II Fund (101 M$) will concentrate on biotherapeutics and medical devices in a more advanced stage of their development.

For more details :  Merck Lumira  Montréal InVivo

Enobia's acquisition by Alexion

2012-01-16

Our sincere congratulations to Enobia on its recent acquisition by Alexion, in a transaction of just over one billion dollars.  Enobia's lead product Asfotase Alfa is a recombinant protein for the treatment of patients suffering from hypophosphatasia, a life-threatening genetic metabolic disease characterized by a defect in bone mineralization, for which there are currently no approved treatment options.  Enobia is a rare example of a true success story in Canadan biotechnology!  Goudreau Gage Dubuc is proud to have collaborated with Enobia and wishes them and Alexion much success in bringing this product to market.

Lundbeck's important wins of appeals before the Federal Court of Appeal

2011-02-22

On November 25, 2010, in a victory for Lundbeck Canada Inc. and its Danish parent H. Lundbeck A/S, clients of Goudreau Gage Dubuc, the Federal Court of Appeal dismissed three appeals by the generic drug makers Genpharm ULC, Apotex Inc. and Cobalt Pharmaceuticals Inc. from a Federal Court judgment prohibiting the Minister of Health from issuing Notices of Compliance to these companies for generic versions of the drug containing escitalopram for use as an antidepressant, until a patent owned by H. Luncbeck A/S expires.

The three cases, which dealt with complex scientific and legal notions, were conducted over a period of almost four years and involved numerous hearings in the Federal Court, national trial court, and the Federal Court of Appeal.  They called upon the testimony of many experts located all over the world familiar with chemistry, psychiatry, pharmacology and economics.

H. Lundbeck A/S and Lundbeck Canada Inc. were advised in these proceedings by Fasken Martineau DuMoulin s.r.l. bringing together Maîtres Marie Lafleur, Julie Desrosiers, Hilal El Ayoubi and Christian Leblanc, teaming up with Goudreau Gage Dubuc s.e.n.c.r.l. LLP with the contribution of Maître Alain Leclerc and Isabelle Pelletier, PhD.

Bravo Theratechnologies! A real Canadian success story!

2010-12-23

Congratulations to the Montreal biopharmaceutical company Theratechnologies on recently receiving approval from the U.S. Food and Drug Administration (FDA) for their lead product EGRIFTATM.  This is welcome news for many HIV-infected patients, as EGRIFTATM is the only treatment approved by the FDA to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.  Theratechnologies has good reason to be very proud - they are one of the very few Canadian biotechnology companies to successfully take a product from discovery all the way to market on their own.  GGD is a proud collaborator of Theratechnologies and wishes them all the best in their continued success!

NOMINATION

2010-10-20

Goudreau Gage Dubuc is proud to announce the nomination of Me Chantal Desjardins as Leading Trademark Practitioner by Who's Who Legal: Canada 2010.  Me Desjardins is currently one of the foremost trademark experts selected amongst the best practitioners in Canada.  Nominees have been selected by Who's Who Legal based upon independent survey work and tight international criteria, with both general counsel and private practice lawyers worldwide.

Extensions of Time in Examination - Trade-marks and Industrial Designs

2010-01-19

Coming into effect on March 11, 2010, the Canadian Intellectual Property Office will generally grant to applicants, if justified, only one extension of time for a period of six months to reply to an Office Action.  Beyond that period, the applicants will need to show exceptional circumstances to be granted an additional period of time.

NOMINATION

2009-10-28

We are pleased to announce that at the IPIC 83rd Annual Meeting held in St. John's, Newfoundland, Me Alain M. Leclerc was nominated member of Council for 2009-2011.  This Canadian professional association is comprised of over 1,700 members from Canada and abroad.  At the same meeting, Me Leclerc was appointed President of the IPIC Committee on Patent Agents Exam Revision.  He is also IPIC Council Representative of the Patent Agents Examining Board.

INVESTMENTS OF MORE THAN 122 MILLIONS $ TO SUPPORT HUMAN HEALTH BIOTECHNOLOGY AND GENOMICS

2009-10-09

The Québec Government will invest $122.77 million, including $30 million for Genome Québec, over the next three years to consolidate Québec’s position in biopharmaceuticals.

The announcement was made on October 8 by Clément Gignac, the Minister of Développement économique, de l’Innovation et de l’Exportation during the BioContact Symposium held in Québec City.  The government’s Biopharmaceutical Stragegy has five goals:  1- step up development and spinoffs from research; 2- support the development of biotechnology firms; 3- support the development of big biopharmaceutical firms; 4- maintain a labor force able to meet the industry’s needs; and 5- promote the world over Québec’s image as a biopharmaceutical hub.

The strategy’s vision:  that Québec be recognized around the world as THE place for global biopharmaceutical investments, notably because of the efficiency of its technology innovation system.

To find out more:
http://www.mdeie.gouv.qc.ca/fileadmin/sites/internet/documents/publications/pdf/ministere/strategie_biopharma_en.pdf

A FIRST IN CANADA WITH ELECTRONIC FILING

2009-07-29

The Canadian Intellectual Property Office (CIPO) recently introduced a new online service for Canadian Applicants allowing the e-filing of PCT applications including the electronic submission of sequence listings.  Based on changes to the PCT Administrative Instructions on July 1, 2009, such e-filing of PCT sequence listings results in considerable savings in PCT filing fees when filing large documents.  Goudreau Gage Dubuc was the first Canadian firm to use this e-filing service and submit electronically, for Xenon Pharmaceuticals Inc., a PCT application and its sequence listing.  Besides facilitating the filing of large documents, this new service brings significant savings to our clients.

Goudreau Gage Dubuc is on the continuous look-out for the latest technologies and best practices to better serve its clientele.

NEW PATENT AGENT

2009-07-27

Goudreau Gage Dubuc is proud to announce that Alain Dumont, Ph.D., has successfully completed the Patent Agent exams.  Alain joimed GGD on January 9, 2006, and his intellectual property areas of practice are biotechnology and pharmaceutical areas.  Click here to view his biography.

APPOINTMENT

2009-05-26

Goudreau Gage Dubuc is proud to announce the nomination of Charles Goyer as Member of the Board of Directors of Montréal InVivo for a mandate of two years.  Montréal InVivo is the trade name for the life sciences and health technologies cluster of Metropolitan Montréal.  This creative cluster is ranked 1st in Canada in terms of the number of research centers and total university research funding.

APPOINTMENT

2009-05-19

Congratulations to Chantal Desjardins, Co-Managing Partner of Goudreau Gage Dubuc, who was recently appointed on the Board of Directors of CEAD Diffusion (Centre des auteurs dramatiques), a non-profit organization established to develop and promote Québec and French-Canadian plays and playwrights.

2009 GENESIS AWARDS

2009-05-14

The 9th Edition of the Genesis Awards Gala, organized by BIOQuébec and which recognizes outstanding achievement by companies and individuals that play a key role in the growth of Québec's biotech, health technology and life sciences industries, was presented in Montréal on May 14, 2009.  During this gala, Goudreau Gage Dubuc, which sponsors the Innovation Award since 2001,  proudly presented its prize to Medicago Inc.  Medicago is a biotechnology company focused on developing protein-based vaccines and biopharmaceuticals.

Goudreau Gage Dubuc LLP – A Rising IP Star!

2008-04-21

GGD is continuing its growth as a specialized intellectual property firm. While the firm has been in operation for the past 40 years, the litigation group is brand new.

Mtre Greg Moore, the partner responsible for the litigation group, and Mtre Chantal Desjardins, who heads the trade-mark group and is the firm’s co-managing partner, recently scored an important victory for a client in the agri-food industry. The client was threatened with an interim injunction that would have forced it to remove several hundred thousand units of its product from store shelves. The Court rejected the request for the injunction, to the great relief of the client. According to Mtre Moore, "We’re working hard to develop a reputation as specialists in intellectual property litigation. We’ll get there thanks to the meticulous preparation of our files – preparation which is the result of close collaboration between our clients and our experienced in-house patent and trade-mark specialists."

GGD’s patent practice is also experiencing strong growth. We have 10 patent agents recognized by the Canadian Intellectual Property Office, which ranks us second in Quebec. According to Mtre Alain Leclerc, the partner responsible for the patent group and co-managing partner, "our attractiveness in the marketplace is responsible for our accelerating growth. Nevertheless, we focus our efforts on quality work and let our growth occur naturally."

Managing Intellectual Property

2007-10-26

Goudreau Gage Dubuc on Managing IP website : Goudreau Gage Dubuc are newcomers to the rankings. Goudreau Gage is a firm to watch and is already garnering high praise from clients. A US lawyer extolled the firm's virtues: "I love working with Goudreau. The firm has a personal touch that is really useful."